Intervacc AB is primarily active in the biotechnology industry.

The main competitors of Intervacc AB in the market include other companies operating in the field of animal health and vaccines. Some of the key competitors of Intervacc AB include Zoetis Inc., Merck Animal Health, Elanco Animal Health, Boehringer Ingelheim, and Virbac. These companies also focus on developing innovative solutions and vaccines for animal diseases.

Intervacc AB is a biotechnology company based in Sweden, specializing in the development and commercialization of vaccines for infectious animal diseases. Founded in 1983, Intervacc has a rich history in the field of animal health and vaccine research. The company's expertise lies in the improvement of vaccine formulas, resulting in effective immunization against diseases such as Strangles and Equine Influenza in horses. With a strong commitment to scientific innovation and animal welfare, Intervacc AB continues to work towards the prevention and control of infectious diseases in animals, ensuring the wellbeing of livestock and pets worldwide.

Intervacc AB, a prominent stock company, has achieved several noteworthy milestones. One such significant accomplishment includes the successful completion of clinical trials for its novel Strangvac® vaccine, designed to combat equine strangles. Furthermore, Intervacc AB obtained a marketing authorization for Strangvac® from the European Medicines Agency, permitting commercialization across the European Union. The company has also secured substantial funding through various partnerships and collaborations, reinforcing its financial stability and promoting further research and development endeavors. With these achievements, Intervacc AB has demonstrated its pioneering efforts in the field of animal health, establishing a strong reputation in the market.

Intervacc AB is primarily present in Sweden, where its headquarters is located. As a biotechnology company, Intervacc AB focuses on the development and commercialization of vaccines for animals. While the company's primary presence is in Sweden, its vaccines have global potential and can benefit regions and countries worldwide. Intervacc AB aims to expand its reach and establish collaborations and partnerships to deliver its innovative animal vaccines across different markets.

Intervacc AB represents values of innovation, dedication, and excellence in the field of biotechnology. The company is committed to developing safe and effective vaccines for both humans and animals. With a focus on preventing infectious diseases, Intervacc AB aims to improve global health and well-being. The corporate philosophy of Intervacc AB revolves around scientific expertise, research-driven development, and collaboration with industry partners. By prioritizing cutting-edge technology, quality assurance, and regulatory compliance, Intervacc AB strives to contribute to the advancement of healthcare.

Analysts currently set an average price target of 96,90 SEK for the Intervacc stock (median: 96,90 SEK), implying +7 921,5 % versus the latest price. The consensus is based on 9 analyst ratings.

Intervacc Analyytikkojen kursstavoitteet 2026

9 analysts currently rate the Intervacc stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Intervacc to generate revenue of 17,70 M SEK and earnings per share of −0,18 SEK.

Intervacc Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Intervacc share trades at 0,11 EUR (1,21 SEK).

The Intervacc share (IVACC.ST) is listed on 3 stock exchanges, including: Frankfurt (2E9.F).

Intervacc AB is a Swedish biotechnology company focused on the development and marketing of vaccines for animals. The company was founded in 2010 and is headquartered in Stockholm, Sweden. The goal of Intervacc AB is to improve the health and well-being of animals by developing and marketing innovative vaccines that help prevent and treat diseases in animals. Intervacc AB specializes in the development of vaccines for animals and offers products for four different market segments: horses, cattle, pigs, and poultry. The product range currently includes four vaccine candidates in various stages of development and marketing. Each vaccine has been specifically developed for a particular animal species and disease. The first vaccine developed by Intervacc AB is Equilis StrepE, a vaccine for horses used to prevent strangles (an upper respiratory tract infection). The company has also developed vaccine candidates for cattle, pigs, and poultry. The cattle vaccine is a vaccine for preventing infections caused by E. coli bacteria, which can lead to serious illnesses in cattle. The pig vaccine is a vaccine for preventing Streptococcus suis, a bacterium that can cause severe illness in pigs. The poultry vaccine is a vaccine designed to protect against infections caused by Campylobacter jejuni, a bacterium that can cause severe gastrointestinal diseases in humans. Currently, Intervacc AB is working on developing new vaccine candidates for other animal species and diseases. The company has an experienced team of biologists, microbiologists, veterinarians, technicians, and other professionals who work closely together to develop vaccines that are safe and effective. The business strategy of Intervacc AB is to establish a strong presence in the animal vaccine market by developing and marketing innovative products that meet the needs of veterinarians, agricultural farms, and other customers. The company works closely with its customers to better understand their needs and ensure that its products meet their requirements. Intervacc AB has also formed strategic partnerships with other companies in the animal health industry to strengthen the distribution of its products and accelerate growth. The company continuously works on improving its technologies and processes to increase the efficiency and quality of its products. Overall, Intervacc AB is an innovative company specializing in the development and marketing of vaccines for animals. The company has developed a wide range of products for different animal species and diseases, and is continuously working on developing new products. With its strong presence in the animal vaccine market and strategic partnerships, Intervacc AB has built a solid foundation for future growth.

odotettu liikevaihto Intervacc on 17,70 M SEK. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Intervacc on −62,45 M SEK. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Intervacc:n hinta-voitto-suhde (P/E) on tällä hetkellä −6,59. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Intervacc-osakkeen arvostusta.

Intervacc:n hinta-myynti-suhde (P/S) on tällä hetkellä 23,26. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Intervacc-osakkeen arvostuskennuslukuna.

Intervacc:n Eulpool-laatuscore on 3/10.

Intervacc:n ISIN on SE0009607252. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Intervacc:n WKN on A2DP4W. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Intervacc:n ticker on IVACC.ST. Tämä pörssinoteeraus käytetään Intervacc-osakkeiden kauppaan pörssissä.

Intervacc maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Intervacc kuuluu sektoriin 'Terveydenhuolto'.

Intervacc:n osingot jaetaan valuutassa SEK.